Edmonson J H, Frytak S, Letendre L, Kvols L K, Eagan R T
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2081-3.
Twenty-eight patients with advanced squamous cell carcinomas and adenocarcinomas of the head and neck were treated with dianhydrogalactitol at a dose of 25 mg/m2 iv on each of 5 consecutive days monthly. All patients except one had received previous surgical and/or radiotherapeutic treatments and 12 had received previous chemotherapy. Disease progression (or symptomatic deterioration) occurred in nine patients after the initial course and in eight others after two courses. In 11 patients, the disease remained stable during at least three courses; however, no instances of objective regression of disease were observed during treatment with dianhydrogalactitol despite significant toxic effects in most patients.
28例晚期头颈部鳞状细胞癌和腺癌患者接受了双去水半乳糖醇治疗，每月连续5天，静脉注射剂量为25mg/m²。除1例患者外，所有患者均曾接受过手术和/或放射治疗，12例曾接受过化疗。9例患者在初始疗程后出现疾病进展（或症状恶化），另有8例在两个疗程后出现进展。11例患者疾病至少在三个疗程中保持稳定；然而，尽管大多数患者有明显的毒性作用，但在双去水半乳糖醇治疗期间未观察到疾病客观缓解的病例。
